Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alembic PharmaceuticalsBOM:533573 +0.33%76 Days Inventory is 369.46 as of Jun. 2026, which is 27% above its 10-year median of 291.87. GuruFocus rates BOM:533573 with a GF Score™ of 76/100 and a GF Value™ of ₹1,100.77 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 920 Drug Manufacturers companies, Alembic Pharmaceuticals ranks worse than 93.15% on this metric.
The historical rank and industry rank for Alembic Pharmaceuticals's Days Inventory or its related term are showing as below:
BOM:533573'
s Days Inventory Range Over the Past 10 Years
Min: 215.42 Med: 291.87 Max: 406.43
Current: 406.43
During the past 13 years, Alembic Pharmaceuticals's highest Days Inventory was 406.43. The lowest was 215.42. And the median was 291.87.
BOM:533573's Days Inventory is ranked worse than 93.15% of 920
companies
in the Drug Manufacturers industry
Industry Median: 165.11
vs BOM:533573: 406.43
Alembic Pharmaceuticals's Days Inventory
declined
from Jun. 2025 (512.49) to Jun. 2026 (369.46).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Alembic Pharmaceuticals's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.25.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Alembic Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 1.17.
Alembic Pharmaceuticals (BOM:533573) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Alembic Pharmaceuticals's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Alembic Pharmaceuticals's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Alembic Pharmaceuticals Days Inventory Related Terms
Alembic Pharmaceuticals Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alembic Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alembic Pharmaceuticals Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alembic Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Alembic Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alembic Pharmaceuticals (BOM:533573) has a Days Inventory of 369.46 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Alembic Pharmaceuticals and its competitors. This is 27% above median its historical median of 291.87. Over the past decade, Alembic Pharmaceuticals' Days Inventory has ranged from 215.42 to 406.43. According to the industry distribution chart, Alembic Pharmaceuticals ranks #857 out of 920 companies in the Drug Manufacturers industry, placing it in the top 93.2%.
Is Alembic Pharmaceuticals' Days Inventory too high?
Alembic Pharmaceuticals' current Days Inventory of 369.46 is 27% above median its 10-year median of 291.87. Over the past 10 years, this metric has ranged from a low of 215.42 to a high of 406.43. The Drug Manufacturers industry median Days Inventory is 165.11. Alembic Pharmaceuticals' value of 369.46 is 123.8% above this industry median. Based on the distribution chart, Alembic Pharmaceuticals ranks #857 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alembic Pharmaceuticals has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alembic Pharmaceuticals' Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alembic Pharmaceuticals ranks #857 out of 920 companies for Days Inventory. This places Alembic Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 165.11. Alembic Pharmaceuticals' value of 369.46 is 123.8% above this benchmark. Historically, Alembic Pharmaceuticals' own Days Inventory has ranged from 215.42 to 406.43 over the past decade. While the company's 10-year median is 291.87 vs. the industry median of 165.11, Alembic Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 165.11, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alembic Pharmaceuticals's current Days Inventory of 369.46 is 123.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Alembic Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 165.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alembic Pharmaceuticals's current Days Inventory is 369.46, which is 27% above median its own 10-year median of 291.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alembic Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alembic Pharmaceuticals (BOM:533573) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,100.77, compared to a current price of ₹841.25 — trading 23.6% below its estimated fair value. The current Days Inventory is 369.46, which is 27% above median its 10-year median of 291.87 and 123.8% above the Drug Manufacturers industry median of 165.11. Alembic Pharmaceuticals' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Alembic Pharmaceuticals (BOM:533573), the current Days Inventory is 369.46 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alembic Pharmaceuticals (BOM:533573) Overvalued in 2026?
Based on GuruFocus' analysis, Alembic Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹841.25 is trading 23.6% below its estimated GF Value™ of ₹1,100.77.
GuruFocus considers Alembic Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BOM:533573:
Days Inventory: 369.46 (27% above median its 10-year median of 291.87)
GF Value™: ₹1,100.77 vs. price of ₹841.25 (23.6% below fair value)
Industry Position: 123.8% above the Drug Manufacturers median (#857 of 920)
No single metric tells the full story. See the BOM:533573 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities.
76GF Score
Get the complete analysis for BOM:533573
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533573 has been successfully added to your 
